Development of a Novel Weighted Ranking Method for Immunohistochemical Quantification of a Heterogeneously Expressed Protein in Gastro-Esophageal Cancers.
Authors
Richards, Cathy ESheehan, Katherine M
Kay, Elaine W
Hedner, Charlotta
Borg, David
Fay, Joanna
O'Grady, Anthony
Hill, Arnold D K
Jirström, Karin
Hopkins, Ann M
Issue Date
2021-03-13Keywords
HER2JAM-A
CANCER
gastro-esophageal cancer
immunohistochemistry
intra-tumoral heterogeneity
tissue microarray
tumor
Metadata
Show full item recordJournal
CancersDOI
10.3390/cancers13061286PubMed ID
33805812Abstract
High expression of Junctional Adhesion Molecule-A (JAM-A) has been linked with poor prognosis in several cancers, including breast cancers overexpressing the human epidermal growth factor receptor-2 (HER2). Furthermore, JAM-A expression has been linked with regulating that of HER2, and associated with the development of resistance to HER2-targeted therapies in breast cancer patients. The purpose of this study was to establish a potential relationship between JAM-A and HER2 in HER2-overexpressing gastro-esophageal (GE) cancers. Interrogation of gene expression datasets revealed that high JAM-A mRNA expression was associated with poorer survival in HER2-positive gastric cancer patients. However, high intra-tumoral heterogeneity of JAM-A protein expression was noted upon immunohistochemical scoring of a GE cancer tissue microarray (TMA), precluding a simple confirmation of any relationship between JAM-A and HER2 at protein level. However, in a test-set of 25 full-face GE cancer tissue sections, a novel weighted ranking system proved effective in capturing JAM-A intra-tumoral heterogeneity and confirming statistically significant correlations between JAM-A/HER2 expression. Given the growing importance of immunohistochemistry in stratifying cancer patients for the receipt of new targeted therapies, this may sound a cautionary note against over-relying on cancer TMAs in biomarker discovery studies of heterogeneously expressed proteins. It also highlights a timely need to develop validated mechanisms of capturing intra-tumoral heterogeneity to aid in future biomarker/therapeutic target development for the benefit of cancer patients.Item Type
ArticleLanguage
enISSN
2072-6694ae974a485f413a2113503eed53cd6c53
10.3390/cancers13061286
Scopus Count
Collections
Related articles
- Cleavage of the extracellular domain of junctional adhesion molecule-A is associated with resistance to anti-HER2 therapies in breast cancer settings.
- Authors: Leech AO, Vellanki SH, Rutherford EJ, Keogh A, Jahns H, Hudson L, O'Donovan N, Sabri S, Abdulkarim B, Sheehan KM, Kay EW, Young LS, Hill ADK, Smith YE, Hopkins AM
- Issue date: 2018 Nov 20
- Junctional adhesion molecule-A is co-expressed with HER2 in breast tumors and acts as a novel regulator of HER2 protein degradation and signaling.
- Authors: Brennan K, McSherry EA, Hudson L, Kay EW, Hill AD, Young LS, Hopkins AM
- Issue date: 2013 May 30
- Human Epidermal Growth Factor Receptor-3 Expression Is Regulated at Transcriptional Level in Breast Cancer Settings by Junctional Adhesion Molecule-A via a Pathway Involving Beta-Catenin and FOXA1.
- Authors: Cruz RGB, Madden SF, Richards CE, Vellanki SH, Jahns H, Hudson L, Fay J, O'Farrell N, Sheehan K, Jirström K, Brennan K, Hopkins AM
- Issue date: 2021 Feb 19
- A Transcriptional Link between HER2, JAM-A and FOXA1 in Breast Cancer.
- Authors: Cruz RGB, Madden SF, Brennan K, Hopkins AM
- Issue date: 2022 Feb 19
- Functional Antagonism of Junctional Adhesion Molecule-A (JAM-A), Overexpressed in Breast Ductal Carcinoma In Situ (DCIS), Reduces HER2-Positive Tumor Progression.
- Authors: Smith YE, Wang G, Flynn CL, Madden SF, MacEneaney O, Cruz RGB, Richards CE, Jahns H, Brennan M, Cremona M, Hennessy BT, Sheehan K, Casucci A, Sani FA, Hudson L, Fay J, Vellanki SH, O'Flaherty S, Devocelle M, Hill ADK, Brennan K, Sukumar S, Hopkins AM
- Issue date: 2022 Mar 3